ZEB2 and non-small cell lung carcinoma: Functionally, continuous low-dose cisplatin inhibited miR-6734-3p, while promoted ZEB2 expressions in CR-NSCLC cells, suggesting that continuous low-dose cisplatin exposure altered miR-6734-3p and ZEB2 expression patterns in CR-NSCLC cells.